These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 37610516)
61. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T; Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616 [TBL] [Abstract][Full Text] [Related]
62. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
63. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients. Meng H; Huang L; Wang J; Zhou Y; Wang M; Yang Z; Hong X Int J Clin Pract; 2021 Dec; 75(12):e14877. PubMed ID: 34525256 [TBL] [Abstract][Full Text] [Related]
64. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
65. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study. Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208 [TBL] [Abstract][Full Text] [Related]
66. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. Frampton JE Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772 [TBL] [Abstract][Full Text] [Related]
67. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820 [TBL] [Abstract][Full Text] [Related]
68. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis. Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902 [TBL] [Abstract][Full Text] [Related]
69. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
70. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932 [TBL] [Abstract][Full Text] [Related]
71. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631 [TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Li L; Huang Q; Sun J; Yan F; Wei W; Li Z; Liu L; Deng J Acta Oncol; 2022 Nov; 61(11):1347-1353. PubMed ID: 36240432 [TBL] [Abstract][Full Text] [Related]
73. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
74. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Remon J; Steuer CE; Ramalingam SS; Felip E Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255 [TBL] [Abstract][Full Text] [Related]
75. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929 [TBL] [Abstract][Full Text] [Related]
76. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681 [TBL] [Abstract][Full Text] [Related]
77. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450 [TBL] [Abstract][Full Text] [Related]
78. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis]. Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338 [No Abstract] [Full Text] [Related]
79. The efficacy of immune checkpoint inhibitors in advanced Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y Front Immunol; 2022; 13():975246. PubMed ID: 36159795 [TBL] [Abstract][Full Text] [Related]